|
A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). |
|
|
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
Other Relationship - Bristol-Myers Squibb; Ipsen |
|
|
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess |
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech |
|
|
Honoraria - Ipsen; Scancell Ltd. |
Consulting or Advisory Role - Ipsen; Scancell Ltd. |
Speakers' Bureau - Bristol-Myers Squibb; Pfizer |
Research Funding - Scancell Ltd. |
Travel, Accommodations, Expenses - BMS Brazil; Ipsen; Merck |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche |
Research Funding - MSD (Inst); Pfizer (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Astellas Medivation; Bayer; BMS Brazil; Claris; Ipsen; Janssen; Novartis |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Janssen |
Consulting or Advisory Role - Astellas Pharma; Eisai; Janssen |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Merck |
|
|
|
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; Octimet (Inst); Pfizer |
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb |
Research Funding - Aveo (Inst); GenMab (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Synthon (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; IPSEN |
Other Relationship - Novartis; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Eisai (Inst); Merck (Inst); Roche (Inst); Viralytics (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen; Roche |
|
Gopalakrishnan Srinivasan |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst) |
|
|
No Relationships to Disclose |